Schrödinger announces collaboration with Novartis

Physics-based US software specialist Schrödinger’s (Nasdaq: SDGR) shares leapt nearly 14% to $22.25 on the back of news that it has entered into a research collaboration and license agreement with Novartis (NOVN: VX) to advance multiple development candidates into Novartis’s portfolio for further development.

The companies also announced an expanded three-year software agreement that substantially increases the Swiss pharma giant’s access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform. This expanded access enables Novartis to deploy Schrödinger’s full suite of drug discovery technologies at industry-leading scale across its research sites. Schrödinger will provide comprehensive support to ensure full integration and optimization of the platform, enabling Novartis to rapidly integrate computation at scale into its drug discovery programs.

Financial terms